Jeil Pharma Holdings Inc (002620.KS)
KRW 7990.0
(-3.5%)
KRW 7990.0
(-3.5%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 794.71 Billion KRW | 0.22% |
| 2022 | 792.96 Billion KRW | 3.99% |
| 2021 | 762.56 Billion KRW | 0.07% |
| 2020 | 761.99 Billion KRW | 4.22% |
| 2019 | 731.14 Billion KRW | 412.23% |
| 2018 | 142.73 Billion KRW | 221.18% |
| 2017 | 44.44 Billion KRW | -92.8% |
| 2016 | 617.27 Billion KRW | 3.79% |
| 2015 | 594.71 Billion KRW | 15.99% |
| 2014 | 512.73 Billion KRW | 13.45% |
| 2013 | 451.96 Billion KRW | 5.89% |
| 2012 | 426.81 Billion KRW | -7.79% |
| 2011 | 462.85 Billion KRW | 7.31% |
| 2010 | 431.3 Billion KRW | 16.73% |
| 2009 | 369.48 Billion KRW | 15.67% |
| 2008 | 319.43 Billion KRW | 4.72% |
| 2007 | 305.02 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 195 Billion KRW | 4.5% |
| 2024 Q1 | 186.61 Billion KRW | -6.9% |
| 2023 Q3 | 194.76 Billion KRW | -2.3% |
| 2023 Q2 | 199.34 Billion KRW | -3.7% |
| 2023 Q4 | 200.43 Billion KRW | 2.91% |
| 2023 FY | 794.71 Billion KRW | 0.22% |
| 2023 Q1 | 207 Billion KRW | 9.29% |
| 2022 Q3 | 195.27 Billion KRW | -8.53% |
| 2022 Q2 | 213.48 Billion KRW | 9.59% |
| 2022 Q1 | 194.79 Billion KRW | 5.52% |
| 2022 FY | 792.96 Billion KRW | 3.99% |
| 2022 Q4 | 189.4 Billion KRW | -3.01% |
| 2021 Q4 | 184.61 Billion KRW | -7.09% |
| 2021 Q1 | 186.32 Billion KRW | -1.95% |
| 2021 Q2 | 192.93 Billion KRW | 3.55% |
| 2021 Q3 | 198.69 Billion KRW | 2.99% |
| 2021 FY | 762.56 Billion KRW | 0.07% |
| 2020 Q4 | 190.02 Billion KRW | 0.14% |
| 2020 FY | 761.99 Billion KRW | 4.22% |
| 2020 Q1 | 189.07 Billion KRW | 2.41% |
| 2020 Q2 | 193.13 Billion KRW | 2.15% |
| 2020 Q3 | 189.75 Billion KRW | -1.75% |
| 2019 Q2 | 184.74 Billion KRW | 4.4% |
| 2019 Q1 | 176.95 Billion KRW | 78.32% |
| 2019 Q4 | 184.61 Billion KRW | 1.38% |
| 2019 Q3 | 182.1 Billion KRW | -1.43% |
| 2019 FY | 731.14 Billion KRW | 412.23% |
| 2018 FY | 142.73 Billion KRW | 221.18% |
| 2018 Q4 | 99.23 Billion KRW | 569.94% |
| 2018 Q3 | 14.81 Billion KRW | -2.15% |
| 2018 Q2 | 15.13 Billion KRW | 1.42% |
| 2018 Q1 | 14.92 Billion KRW | -4.38% |
| 2017 Q2 | 8.82 Billion KRW | -94.51% |
| 2017 FY | 44.44 Billion KRW | -92.8% |
| 2017 Q1 | 160.75 Billion KRW | -72.68% |
| 2017 Q3 | 10.44 Billion KRW | 18.36% |
| 2017 Q4 | 15.61 Billion KRW | 49.53% |
| 2016 Q1 | 154.96 Billion KRW | 0.0% |
| 2016 Q3 | 9.85 Billion KRW | 7.26% |
| 2016 Q4 | 588.42 Billion KRW | 5870.69% |
| 2016 Q2 | 9.18 Billion KRW | -94.07% |
| 2016 FY | 617.27 Billion KRW | 3.79% |
| 2015 FY | 594.71 Billion KRW | 15.99% |
| 2015 Q4 | - KRW | -100.0% |
| 2015 Q3 | 152.11 Billion KRW | 3.35% |
| 2015 Q2 | 147.19 Billion KRW | 3.01% |
| 2015 Q1 | 142.89 Billion KRW | 10.89% |
| 2014 Q2 | 132.87 Billion KRW | 12.21% |
| 2014 Q1 | 118.41 Billion KRW | 0.59% |
| 2014 FY | 512.73 Billion KRW | 13.45% |
| 2014 Q4 | 128.86 Billion KRW | -2.8% |
| 2014 Q3 | 132.57 Billion KRW | -0.22% |
| 2013 Q3 | 114.44 Billion KRW | -0.91% |
| 2013 Q4 | 117.71 Billion KRW | 2.86% |
| 2013 FY | 451.96 Billion KRW | 5.89% |
| 2013 Q1 | 104.3 Billion KRW | 5.66% |
| 2013 Q2 | 115.49 Billion KRW | 10.73% |
| 2012 Q4 | 98.72 Billion KRW | -8.03% |
| 2012 FY | 426.81 Billion KRW | -7.79% |
| 2012 Q1 | 107.52 Billion KRW | -5.73% |
| 2012 Q2 | 113.23 Billion KRW | 5.31% |
| 2012 Q3 | 107.33 Billion KRW | -5.21% |
| 2011 FY | 462.85 Billion KRW | 7.31% |
| 2011 Q4 | 114.06 Billion KRW | -10.86% |
| 2011 Q3 | 127.95 Billion KRW | 14.12% |
| 2011 Q2 | 112.12 Billion KRW | 3.15% |
| 2011 Q1 | 108.7 Billion KRW | -1.09% |
| 2010 Q2 | 112.1 Billion KRW | 13.23% |
| 2010 FY | 431.3 Billion KRW | 16.73% |
| 2010 Q4 | 109.89 Billion KRW | -0.37% |
| 2010 Q3 | 110.3 Billion KRW | -1.61% |
| 2010 Q1 | 99 Billion KRW | 5.63% |
| 2009 Q1 | 82.33 Billion KRW | 4.0% |
| 2009 Q2 | 95.77 Billion KRW | 16.33% |
| 2009 Q3 | 97.64 Billion KRW | 1.95% |
| 2009 Q4 | 93.72 Billion KRW | -4.02% |
| 2009 FY | 369.48 Billion KRW | 15.67% |
| 2008 Q3 | 80.49 Billion KRW | -1.67% |
| 2008 Q2 | 81.85 Billion KRW | 5.23% |
| 2008 Q1 | 77.79 Billion KRW | -1.59% |
| 2008 Q4 | 79.16 Billion KRW | -1.65% |
| 2008 FY | 319.43 Billion KRW | 4.72% |
| 2007 Q1 | 71.83 Billion KRW | 0.0% |
| 2007 Q4 | 79.04 Billion KRW | 4.15% |
| 2007 Q3 | 75.89 Billion KRW | -3.01% |
| 2007 Q2 | 78.24 Billion KRW | 8.93% |
| 2007 FY | 305.02 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -479.197% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 29.796% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | -24.476% |
| HANDOK Inc. | 522.74 Billion KRW | -52.028% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -487.056% |
| Yuhan Corporation | 1858.98 Billion KRW | 57.25% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | -19.689% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -1429.618% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 46.695% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -489.07% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -114.476% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -797.033% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -368.671% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -254.061% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -479.197% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -918.169% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -426.053% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -809.662% |
| JW Holdings Corporation | 928.07 Billion KRW | 14.369% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | -32.285% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 52.395% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -6.17% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -296.903% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -339.645% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -304.752% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | -9.405% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -479.197% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 47.525% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 42.216% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -6.17% |
| Yuhan Corporation | 1858.98 Billion KRW | 57.25% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -238.316% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -33.663% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -6.17% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -172.042% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -184.901% |
| CKD Bio Corp. | 160.35 Billion KRW | -395.603% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -50.813% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -120.076% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -244.937% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -296.903% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 9.669% |
| Boryung Corporation | 859.62 Billion KRW | 7.551% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -531.085% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -114.476% |
| JW Lifescience Corporation | 206.86 Billion KRW | -284.179% |